Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.82 |
| ▸ | CA1 | P00915 | 6/20 | 0.67 |
| ▸ | CA2 | P00918 | 6/20 | 0.67 |
| ▸ | CA7 | P43166 | 6/20 | 0.67 |
| ▸ | CA9 | Q16790 | 6/20 | 0.67 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.57 |
| ▸ | CASR | P41180 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364392 | 0.90 | KDR (1.00) | KDRCA1CA2CA7CA9 | |
| SCHEMBL118026 | 0.90 | KDR (1.00) | KDRCA1CA2CA7CA9 | |
| SCHEMBL4548158 | 0.86 | KDR (0.90) | KDRCA1CA2CA7CA9 | |
| SCHEMBL3644352 | 0.86 | KDR (0.84) | KDRCA1CA2CA7CA9 | |
| SCHEMBL618575 | 0.85 | KDR (0.82) | KDRCA1CA2CA7CA9 | |
| Cloflucarban SCHEMBL27537485 | 0.84 | KDR (0.88) | KDRCA1CA2CA7CA9 | |
| SCHEMBL19677976 | 0.84 | KDR (0.88) | KDRCA1CA2CA7CA9 | |
| Cloflucarban SCHEMBL119821 | 0.84 | KDR (0.88) | KDRCA1CA2CA7CA9 | |
| SCHEMBL10220062 | 0.84 | KDR (0.88) | KDRCA1CA2CA7CA9 | |
| SCHEMBL12413876 | 0.84 | KDR (0.82) | KDRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915806-B1 | QUINOLINE COMPOUND AND USE THEREOF | UNIV SHENYANG PHARMACEUTICAL (CN) | 2018-04-25 | — | — | EP | disclosed |
| US-9783499-B2 | Quinoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20150307453-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR APPLICATIONS | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2015-10-29 | — | — | US | disclosed |
| EP-2915806-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307453-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR APPLICATIONS | MET, RAF1, RET | KDR 297/4885CA1 1815/4885CA2 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.